Autologous adipose derived mesenchymal stem cell therapy (Hope Biosciences)

N/A

Report date: 2025/03/12 10:27:39

Base Information

Drug NameAutologous adipose derived mesenchymal stem cell therapy (Hope Biosciences)
Drug Alias Name自体脂肪来源的间充质干细胞疗法HB-adMSCsAutologous HB-adMSCs
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Adipose-derived
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Brain Injuries, Traumatic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesHope Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesCelltex Therapeutics CoThe University Of Texas Health Science Center At Houston
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Brain Injuries, Traumatic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A